Fordyce Marshall sold $702K of VERA

Vera Therapeutics (NASDAQ:VERA) shares rose about 9% after the FDA approved Trutakna under the accelerated approval pathway for IgA nephropathy. Interim Phase 3 ORIGIN 3 data for 203 participants showed statistically significant proteinuria reductions vs placebo (42% at 36 weeks; 46% UPCR reduction from baseline). Confirmatory benefit depends on ongoing ORIGIN 3 results expected in Q3 2026.

Vera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. In ORIGIN 3 interim analysis, TRUTAKNA cut UPCR 46% vs baseline and 42% vs placebo (statistically significant). Safety in 428 patients included infections (32% vs 28%) and injection reactions (30% vs 5%); long-term kidney benefit pending Q3 2026.

Vera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk of progression. In ORIGIN 3 interim analysis, TRUTAKNA reduced proteinuria (UPCR) 46% vs baseline and 42% vs placebo at 36 weeks (p<0.0001). Common AEs were infections and local reactions; long-term kidney benefit not yet established.

Vera Therapeutics’ (NASDAQ:VERA) shares rose about 1% to $41.60 Monday after gaining ~30% over the past month. The company is awaiting an FDA decision due July 7 on accelerated approval of atacicept for IgA nephropathy, supported by ORIGIN 3 interim data showing proteinuria reductions vs placebo. eGFR results are expected in Q3 2026.

U.S. stock index futures rose premarket as investors returned from a holiday. Scilex Holding gained 7% on a binding term sheet for a proposed $100M strategic investment. Vera Therapeutics rose 6% ahead of a July 7 FDA PDUFA decision for atacicept. Solaris Energy Infrastructure rose 3.9% after Wolfe Research coverage and a ~$55M acquisition. Strategy rose 3.4% after adopting a framework to selectively monetize up to $1.25B in Bitcoin holdings.

Vera Therapeutics’ (NASDAQ:VERA) shares rose ahead of an FDA PDUFA decision on July 7 for its BLA seeking accelerated approval of atacicept in adults with IgA nephropathy. The FDA will decide on the application; Vera says it aligned on a revised ORIGIN 3 eGFR analysis plan, with results expected in Q3 2026.